Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Articles by Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Future of ALK-rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Testing for ALK Rearrangements in mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Subsequent Lines of Therapy in ALK-rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Updates Informing the Management of ALK-rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Updates Informing the Management of NTRK+ NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

NTRK Gene Fusions in NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Future Directions for ROS1 rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

ALKA-372-001, STARTRK-1, and STARTRK-2 Trials

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Current Management of ROS1 rearranged NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

ROS1 Rearrangements in mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Molecular Testing for NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Overview of Rare Driver Alterations in NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Development of KRAS G12C-Targeted Therapy in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Systemic Therapy for KRAS+ Advanced NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Counseling Patients With NSCLC When KRAS is Detected

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Testing for KRAS Mutations in NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

KRAS Mutations in Solid Tumors

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Current Management of Oncogene-Driven NSCLC

ByPaul Bunn, MD, University of Colorado Cancer Center,Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 3rd 2020

Dr. Riess Discusses PD-L1 Expression in Thymic Malignancies

ByJonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 7th 2014

Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray.

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Articles by Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

Future of ALK-rearranged mNSCLC

Testing for ALK Rearrangements in mNSCLC

Subsequent Lines of Therapy in ALK-rearranged mNSCLC

Updates Informing the Management of ALK-rearranged mNSCLC

Updates Informing the Management of NTRK+ NSCLC

NTRK Gene Fusions in NSCLC

Future Directions for ROS1 rearranged mNSCLC

ALKA-372-001, STARTRK-1, and STARTRK-2 Trials

Current Management of ROS1 rearranged NSCLC

ROS1 Rearrangements in mNSCLC

Molecular Testing for NSCLC

Overview of Rare Driver Alterations in NSCLC

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

Development of KRAS G12C-Targeted Therapy in NSCLC

Systemic Therapy for KRAS+ Advanced NSCLC

Counseling Patients With NSCLC When KRAS is Detected

Testing for KRAS Mutations in NSCLC

KRAS Mutations in Solid Tumors

Current Management of Oncogene-Driven NSCLC

Dr. Riess Discusses PD-L1 Expression in Thymic Malignancies

Trending on OncLive

Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC

Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm

FDA Approves Guardant360 as Encorafenib Companion Diagnostic in BRAF V600E-Mutant mCRC

INAVO123 Set to Determine Upfront Role of Inavolisib in PIK3CA-Mutant, HR+ Breast Cancer

Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer